President Biden signed a sweeping executive order aimed at increasing competition. Funding for digital health companies continues to break records. And the FDA chief calls for an investigation of the agency's approval of Alzheimer's drug Aduhelm.
Hosted on Acast. See acast.com/privacy for more information.
